Cancer Clinical Investigation

Search results

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  21/03/25

  1 item of Media coverage

  Press/Media

• Mount Sinai Leads Phase 3 Myelofibrosis Trial

  Mascarenhas, J.

  20/03/25

  1 item of Media coverage

  Press/Media

• Findings from Stanford University Yields New Findings on Life Science (Deciphering the Impact of Genomic Variation On Function)

  Reddy, E. P.

  20/03/25

  1 item of Media coverage

  Press/Media

• Understanding Esophageal Squamous Cell Carcinoma: Pathophysiology, Knowledge Gaps, and Promising Developments

  Goodman, K.

  19/03/25

  1 item of Media coverage

  Press/Media

• Mount Sinai Leads Phase 3 Trial in Myelofibrosis Treatment

  Mascarenhas, J.

  19/03/25

  1 item of Media coverage

  Press/Media

• Mount Sinai Leads Phase 3 Trial in Myelofibrosis Treatment

  Mascarenhas, J.

  19/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  17/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising In Phase 1 Trial At Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  17/03/25

  1 item of Media coverage

  Press/Media

• Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai

  Marron, T., Friedlander, P. & Bhardwaj, N.

  17/03/25

  1 item of Media coverage

  Press/Media

• Weekly: Karyopharm Therapeutics (KPTI: $6.75) falls for a fourth consecutive week, a four-week fall of 27%; -14c [2.0%] Vol Index 1.3 [1 is avg]

  Mascarenhas, J.

  15/03/25

  1 item of Media coverage

  Press/Media

• -NTx Establishes Scientific Advisory Board with Distinguished Leaders in Oncology

  Oh, W. & Marron, T.

  14/03/25

  1 item of Media coverage

  Press/Media